Rxcurve
HCPCS J9196 · per 200 MG

Inj gemcitabine hcl (accord)

This code is not in the latest file (4Q26). It was last listed in 2Q26.

Payment limit per 200 MG, by effective quarter, 2Q23 to 2Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9196

No NDCs mapped to this code in the 4Q26 crosswalk.

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
2Q26 $5.29 $0.00 200 MG Inj gemcitabine hcl (accord) v1, posted September 15, 2026
1Q26 $5.29 $0.00 200 MG Inj gemcitabine hcl (accord) v1, posted September 15, 2026
4Q25 $5.29 $0.00 200 MG Inj gemcitabine hcl (accord) v1, posted September 8, 2026
3Q25 $5.29 −$3.363 200 MG Inj gemcitabine hcl (accord) v1, posted March 10, 2026
2Q25 $8.653 −$0.684 200 MG Inj gemcitabine hcl (accord) v1, posted March 10, 2026
1Q25 $9.337 +$0.814 200 MG Inj gemcitabine hcl (accord) v1, posted December 19, 2025
4Q24 $8.523 +$0.741 200 MG Inj gemcitabine hcl (accord) v1, posted June 11, 2025
3Q24 $7.782 +$3.547 200 MG Inj gemcitabine hcl (accord) v1, posted June 11, 2025
2Q24 $4.235 −$4.54 200 MG Inj gemcitabine hcl (accord) v1, posted March 11, 2025
1Q24 $8.775 +$5.086 200 MG Inj gemcitabine hcl (accord) v1, posted December 19, 2024
4Q23 $3.689 −$0.026 200 MG Inj gemcitabine hcl (accord) v1, posted October 10, 2024
3Q23 $3.715 −$0.138 200 MG Inj gemcitabine hcl (accord) v1, posted June 5, 2024
2Q23 $3.853 – 200 MG Inj gemcitabine hcl (accord) v1, posted February 23, 2024

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files